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Management of Scorpion Envenomation 
Scorpion stings are a major public health problem in many underdeveloped tropical countries. 
For every person killed by a poisonous snake, 10 are killed by a poisonous scorpion. Out of 
1500 scorpion species, 50 are dangerous to humans. Almost all of these lethal scorpions, ex-
cept the Hemiscorpius species, belong to the scorpion family called the Buthidae. The lethal 
members of the Buthidae family include the genera of Buthus, Parabuthus, Mesobuthus, Ti-
tyus, Leiurus, Androctonus, and Centruroides. These lethal scorpions 
are found generally in the given distribution: 
 
Buthus - Mediterranean area  
Parabuthus - Western and Southern Africa  
Mesobuthus - Asia  
Tityus - Central and South America, Carib-
bean  
Leiurus - Northern Africa and Middle East  
Androctonus - Northern Africa to Southeast 
Asia  
Centruroides - Southwest USA, Mexico, Central America  
 
Scorpion stings cause a wide range of conditions, from severe local skin reactions to neu-
rologic, respiratory, and cardiovascular collapse. Potency of venom varies with the species, 
with some producing only a mild flu and others producing death within an hour. Venom depos-
ited via intravenous route can cause symptoms only 4-7 minutes after the injection, with a peak 
tissue concentration in 30 minutes (progress to a maximum severity within 5 hours) and an 
overall toxin elimination half-life of 4.2-13.4 hours through the urine. The symptoms generally 
persist for 10-72 hours. 
Mortality/Morbidity: 
Most deaths occur during the first 24 hours after the sting and are secondary to respiratory or 
cardiovascular failure. Children and elderly persons are at the greatest risk for morbidity and 
mortality.  
Signs and Symptoms: 
The signs of the envenomation are determined by the scorpion species, venom composition, 
and the victim's physiological reaction to the venom. Signs and symptoms do not have an ap-
parent sequence. Thus, predicting the evolution of signs over time is difficult. Furthermore, a 
false recovery followed by a total relapse is common.  
A person who has been stung by a scorpion usually has four signs, with the most common be-
ing mydriasis, nystagmus, hypersalivation, dysphagia, and restlessness. The mode of death is 
usually via respiratory failure secondary to anaphylaxis, bronchoconstriction, bronchorrhea, 
pharyngeal secretions, and/or diaphragmatic paralysis, even though venom-induced multior-
gan failure plays a large role. Children present with the same symptoms and signs as adults, 
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except their symptoms are more severe and protracted. 
Lab Studies 
• Electrolyte evaluation is warranted in patients with venom-induced salivation, vomiting, and diarrhoea. 
• Coagulation parameters should be measured for venom-induced defibrination because, at high concentra-
tions, the venom is an anticoagulant. 
• Glucose levels should be measured to evaluate for hyperglycaemia from liver and pancreas dysfunction. 
• Creatine kinase and urinalysis help evaluate for venom-induced excessive motor rhabdomyolysis. 
• Patients may have increased LFTs levels from venom-induced liver cell destruction.  
Local treatment:  
1. A negative-pressure extraction device (i.e., the extractor) may be useful, although the benefit is unproven. 
Apply it to the sting site after incision. Oral extraction is contraindicated. 
2. Use ice bags to reduce pain and to slow the absorption of venom via vasoconstriction. This is most effec-
tive during the first 2 hours following the sting. 
3. Immobilize the affected part in a functional position below the level of the heart to delay venom absorption. 
4. Calm the patient to lower the heart rate and blood pressure, thus limiting the spread of the venom. 
5. For medical delay secondary to remoteness, consider applying a lymphatic-venous compression wrap 1 
inch proximal to the sting site to reduce superficial venous and lymphatic flow of the venom but not to stop the 
arterial flow. Only remove this wrap when the provider is ready to administer systemic support. The drawback 
of this wrap is that it may intensify the local effects of the venom. 
6. Apply a topical or local anaesthetic agent to the wound to decrease paresthesia; this tends to be more ef-
fective than opiates. 
7. Administer local wound care and topical antibiotic to the wound.  
Drug Therapy: 
1. Administer tetanus prophylaxis 
2. Administer systemic antibiotics if signs of secondary infection occur 
3. For hyperdynamic cardiovascular changes, administration of a combination of beta-blockers with sympa-
thetic alpha-blockers is most effective in reversing this venom-induced effect. Avoid using beta-blockers 
alone because this leads to an unopposed alpha-adrenergic effect. Also, nitrates can be used for hyperten-
sion and myocardial ischemia. For hypodynamic cardiac changes, a titrated monitored fluid infusion with 
afterload reduction helps reduce mortality. A diuretic may be used for pulmonary edema in the absence of 
hypovolemia, but an afterload reducer, such as prazosin, nifedipine, nitroprusside, hydralazine, or angio-
tensin-converting enzyme inhibitors, is better. Inotropic medications, such as digitalis, have little effect, 
while dopamine aggravates the myocardial damage through catecholaminelike actions. Dobutamine seems 
to be a better choice for the inotropic effect. Finally, a pressor such as norepinephrine can be used as a last 
resort to correct hypotension refractory to fluid therapy.  
4. Administer atropine to counter venom-induced parasympathomimetic effects. 
5. Administer barbiturates and/or a benzodiazepine continuous infusion for severe excessive motor activity.  
6. Administer Benzodiazepines to counteract excessive motor activity and nervous system excitation. 
7. The use of steroids to decrease shock and edema is of unproven benefit.  
      Note: Scorpion Antivenom is not available in Pakistan 
 
Activity:  
Rest and immobilisation of sting site is recommended to prevent rapid absorption of the venom into the circula-
tion. 
 
Inpatient Care:  
Inpatient care is dictated by the severity of the envenomation and consists of stabilising the patient, providing 
supportive therapies, and preventing complications. 
Outpatient Care:  
Patients displaying local nonascending reactions to the venom may be discharged after six hours of observa-
tion, with close follow-up. If the patient was treated with a pressure bandage, the symptoms may be delayed 
and inpatient observation is warranted. Inform the patient about the possibility of persistent pain or paresthesia 
at the sting site. 
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Methanol is a highly toxic alcohol found in a variety of commercial products from paint stripper to industrial solvents to 
xerographic copier solution etc. Post ingestion, it is rapidly absorbed from the gastrointestinal tract and distributed in 
body water. The natural progression of the poisoning leads to accumulation of toxic metabolites, including formic acid 
and formaldehyde. It is these metabolites that have the ability to induce metabolic acidosis, nausea/vomiting, seizures, 
stupor, coma, calcium oxaluria, acute tubular necrosis, blindness and death. The amount of methanol ingested to toxic 
proportions varies among individuals. A dose of more than 30 ml methanol is considered potentially lethal. 
Obtaining blood levels of methanol after a toxic ingestion may be difficult, since it metabolises to respective metabolites 
in the blood. It is for this reason that both methanol concentration and acid base balance as determined by the serum 
electrolyte (anion gap) and /or arterial blood gas analysis should be frequently monitored. Methanol concentrations in 
excess of 50 mg/dL are thought to be an absolute indication for the treatment with an antidote 
The treatment plan is based on three ‘specific’ modalities: suppression of metabolism by alcohol dehydrogenase to toxic 
products, dialysis to enhance removal of methanol and its toxic product, and alkalinization to counteract metabolic acido-
sis. 
So, a general treatment principle would consist of: 
1. Emptying the stomach (if indicated) 
2. Correction of the acidosis 
3. Ethanol or Fomepizole administration to inhibit formation of toxic metabolites 
4. Rapid reduction of body burden of both methanol and formate by haemodialysis 
5. Intensive supportive care for multiple organ/system failure 
Suggested dosing regimen for Ethanol includes: 
 
Note: In an emergency, an equivalent amount of any alcoholic drink may be administered orally. 
Blood ethanol concentrations needs to be monitored hourly to maintain a concentration of >100 mg/Dl 
Fomepizole, an FDA approved antidote, is quite expensive and probably not found in Pakistan. Dose for Fomepizole is 
15 mg/kg IV followed by 10 mg/kg IV every 12 hours. After withdrawing appropriate dose from the vial, Fomepizole 
should be diluted to at least 100 mL using 0.9% Sodium Chloride or 5% Dextrose injection. 
 For methanol poisoning, folic acid 1mg/kg (50-70 mg) IV every 4 hours for the first 24 hours for a total of 6 doses is also 
added to the therapy plan to replenish folate dependent systems which are responsible for the oxidation of formic acid to 
CO in humans. Strong clinical data for this addition however is scarce. Source: http://www.pulsepakistan.com/
  Oral 
  
Intravenous 
  
Loading dose 1 mL/kg of 95% ethanol, diluted 10 mL/kg of 10% ethanol in 5% dex-
trose over 30-60 minutes 
Maintenance dose 0.1-0.2ml/kg/hour of 95% ethanol, diluted 1-2 mL/kg of 10% ethanol in 5% dex-
trose over 30 minutes 
Managing Toxic Methanol poisoning  
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The need of the hour is to document all these fatalities and prepare a data base not only for the cases but also of the therapies tried 
out on those who were lucky enough to make it to the hospitals alive. Physicians and Pharmacists  should document their experi-
ences and fortify in an effort to be better prepared for any such event in the future. 
 
 
 
 
Therapeutic Drug Monitoring (TDM) is defined as the use of drug concentrations to optimise drug therapy for 
individual patient. The idea that intensity and duration of pharmacological response is dependent on serum 
concentration as first r ported by Marshalland, then tested for the screening of antimalarials during World 
War II. Since 1960s extensive research was directed in developing specific and sensitive analytical methods 
for serum drug concentration measurements.  
 
Currently, drug concentration assays most widely available in hospital laboratory are for: antiepileptics 
(Carbamazepine, Ethosuximide, Phenobarbital, Phenytoin and Valproic acid), cardiac drugs (Digoxin, Pro-
cainamide and Quinidine), antibiotics (Aminoglycosides and Vancomycin), Theophylline, Cyclosporine and 
Lithium.  
As a general rule, the serum drug concentrations are affected by following factors: 
• Patient’s renal or hepatic function 
• Protein binding capacity (Albumin level) 
• Electrolytes (particularly K+ and Mg+2) 
• Sample timing with respect to dose (loading as well as maintenance) and route  
• Drug-Drug Interaction 
• Drug-Food interaction  
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Adverse Drug Reaction Update 
    
Warfarin and Alopecia 
Alopecia due to warfarin-therapy has occurred; incidence range from 5 percent to reports as high as 78%. 
Alopecia is reported to occur after both acute and chronic use .The response is directly related to the highest 
warfarin dose given and not to the duration of treatment. Hair is shed diffusely two or three months after an 
adequate dose of the drug. Marked hair loss is rare and hair growth resumes once warfarin is discontinued
( Alopecia may recur upon warfarin re-challenge). Two case reports in which ubidecarenone (30 milligrams 
daily) reversed warfarin-induced alopecia despite continuation of warfarin therapy are available (Micromedix 
Facts About Therapeutic Drug Monitoring  
